MARKET WIREStock Titan • 1d ago
A 1-for-10 to 1-for-100 reverse split goes to iSpecimen (ISPC) voters October 30.Stock Titan report covering iSpecimen Inc. (ISPC) market action, institutional positioning, and fundamental catalysts.
Why ISPC Stock advanced +0.82% Today — RQD Quant Desk Flash
$0.83 +0.82% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.83
iSpecimen Inc. (ISPC) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $2.1M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ISPC Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ISPC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, iSpecimen Inc. (NASDAQ: ISPC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $0.83 (+0.82% 1D, market cap $2.1M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ISPC ranks #817 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ISPC compare to BIAF and ONMD in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), ISPC carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 11.2%, and ROIC of -35.0%. By comparison, BIAF (bioAffinity Technologies Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $3.7M) and ONMD (OneMedNet Corp (Class A)) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $25.4M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ISPC?
▼
Per ISPC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001558569), iSpecimen Inc. generated $1.9M in revenue (-79.2% YoY), -$10.5M in net income, and -$4.2M in free cash flow against $9.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.83 (-0.04%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-12% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ISPC)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY ISPC SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+9/20 pts (30% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 11.2% Gross Margin
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (27% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$1.08-11.1% Next Q
38
Q2 (-2Q)Grade E$0.96-9.4% Next Q
35
Q3 (-1Q)Grade E$0.87-4.6% Next Q
33
CurrentGrade E$0.83-9.6% Hist 90D α
30
Trajectory: E (38) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ISPC Turnaround Squeeze
While ISPC currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.20) and Max Pain ($0.87) forces dealer call-delta covering toward $34.61.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ISPC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ISPC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ISPC Stock advanced +0.82% Today — RQD Quant Desk Flash
iSpecimen Inc. (ISPC) advanced +0.82% to $0.83, trading at 2% of its 52-week range ($0.75 – $32.96). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($0.75 – $32.96) with RSI-14 at 33.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.83 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 11.2% gross margin and $0 annual free cash flow.
Live ISPC Headlines & Catalysts
MARKET WIREBenzinga • 1d ago
12 Health Care Stocks Moving In Thursday's After-Market SessionBenzinga report covering iSpecimen Inc. (ISPC) market action, institutional positioning, and fundamental catalysts.
CATALYSTStock Titan • 1d ago
Healthy donor blood is generally shipped the day it's collected, aiming for next-day delivery.Stock Titan report covering iSpecimen Inc. (ISPC) market action, institutional positioning, and fundamental catalysts.
RISK WATCHhttps://www.siam.in/ • 1d ago
iSpecimen (ISPC) Falls -0.76% — Watching $0.86 Support 2026-10-20 - Algorithmic Stock Pickshttps://www.siam.in/ report covering iSpecimen Inc. (ISPC) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 4d ago
12 Health Care Stocks Moving In Friday's Pre-Market SessionGainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million. Intensity Therapeutics
MARKET WIREChartMill • 4d ago
After-Hours Market Movers: Oct. 29, 2026 Gainers and LosersPostmarket movers for Oct. 29, 2026: top after-hours gainers included SLGB, BURU and WKHS, while GCTK, LNAI and ATEC led the decliners.
MARKET WIREYahoo • 4d ago
iSpecimen Offers Next-Day Healthy Donor Blood and Launches Development of AI AgentWoburn, Massachusetts--(Newsfile Corp. - October 29, 2026) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), a provider of human biospecimens, today announced expanded access to fully consented, prospective
MARKET WIREBenzinga • 12d ago
12 Health Care Stocks Moving In Thursday's Pre-Market SessionGainers Biohaven (NYSE:BHVN) shares increased by 39.3% to $16.37 during Thursday's pre-market session. The company's market cap stands at $1.7 billion. Vogenx (NASDAQ:VOGX) stock rose 22.05% to $24.89. The
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ISPC)
- ✓Walkthrough of ISPC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ISPC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -84.63%⚡ TESTING RESISTANCE
2026-11-03O $0.80H $0.83L $0.80C $0.83VOL 543.3K
RES: $0.92SUP: $0.72SMA50: $1.20SMA200: $4.71
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ISPC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. -79.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on ISPC today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ISPC. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ISPC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ISPC)
Health Care Rank #817 of 1015
⚔️ BIAF vs ISPC Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ISPC vs. BIAF, ONMD, MXCT, NRC)
Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, iSpecimen Inc. (ISPC) ranks #817 by composite RQD confidence (30/100, grade E) and #994 by equity capitalization ($2.1M). Within this direct 5-issuer industry benchmark cohort, NRC leads on earnings valuation at 44.8x trailing P/E, while NRC leads on capital efficiency and profitability with 21.0% ROIC and — gross margin. NRC currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with ISPC at 30/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ISPC
ACTIVE
iSpecimen Inc. | E | 30/100 | — | 11.2% | -35.0% | +0.82% | $2.1M | Benchmark Subject |
| BIAF bioAffinity Technologies Inc. | E | 29/100 | — | — | -35.0% | +2.75% | $3.7M | /biaf-vs-ispc → |
| ONMD OneMedNet Corp (Class A) | E | 26/100 | — | -30.0% | -35.0% | +1.42% | $25.4M | /onmd-vs-ispc → |
| MXCT MaxCyte Inc. | E | 34/100 | — | 96.0% | -27.1% | -8.80% | $164.1M | /mxct-vs-ispc → |
| NRC NRC Health | C+ | 67/100 | 44.8x | — | 21.0% | +1.80% | $527.1M | /nrc-vs-ispc → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001558569 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), iSpecimen Inc. (ISPC) reported GAAP revenue of $1.9M (-79.2% vs. FY2024 revenue of $9.3M , and -80.6% cumulative change since FY2023) , GAAP net income of -$10.5M, operating cash flow of -$4.2M, and free cash flow of -$4.2M (+48.9% YoY). On the balance sheet, ISPC closed FY2025 with $9.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.9M | -$10.5M | -$4.2M | -$4.2M | $9.5M | — |
| FY2024 (FY) | 2024-12-31 | $9.3M | -$12.5M | -$8.3M | -$8.3M | $9.4M | — |
| FY2023 (FY) | 2023-12-31 | $9.9M | -$11.1M | -$5.8M | -$5.8M | — | — |
3. ISPC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ISPC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, iSpecimen Inc. (NASDAQ: ISPC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $0.83 (+0.82% 1D, market cap $2.1M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ISPC ranks #817 in composite RQD confidence.
How does ISPC compare to BIAF and ONMD in the Health Care sector?
Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), ISPC carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 11.2%, and ROIC of -35.0%. By comparison, BIAF (bioAffinity Technologies Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $3.7M) and ONMD (OneMedNet Corp (Class A)) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $25.4M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ISPC?
Per ISPC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001558569), iSpecimen Inc. generated $1.9M in revenue (-79.2% YoY), -$10.5M in net income, and -$4.2M in free cash flow against $9.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ISPC trading relative to its 50-day, 200-day, and 52-week technical levels?
ISPC last traded at $0.83 (+0.82% on volume of 108,488 shares), positioning the stock -30.83% below its 50-day simple moving average ($1.20) and -82.38% below its 200-day simple moving average ($4.71). Across its 52-week range of $0.75 to $32.96, ISPC sits at the 0.2% percentile with a 14-day RSI of 33.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.93).
ROARABLE RATING BRIEF • RQD 30/100 (E)
✓ SEC XBRL & RQD VERIFIED
ISPC — iSpecimen Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
iSpecimen Inc. (ISPC) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.83 (+0.82% 1D, market capitalization $2.1M).
- Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 11.2%, operating margin of -60.0%, and free cash flow yield of —.
- Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (7/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
ISpecimen Inc. (ISPC) is a NASDAQ-listed issuer classified in the Health Care sector and the Biotechnology: Commercial Physical & Biological Resarch industry. Gross margin is reported at 11.2% per the market data section.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), iSpecimen Inc. (ISPC) reported $1.9M in annual revenue (up from $9.3M in FY2024, -79.2% YoY) and -$10.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($9.9M revenue, -$11.1M net income) through FY2025, ISPC scaled operating cash flow to -$4.2M and free cash flow to -$4.2M, backed by $9.5M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 30/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.75 – $32.96 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Biotechnology: Commercial Physical & Biological Resarch (Health Care), ISPC carries a macro regime beta of 1.00 and gross margin of 11.2%.
- Key Question #1: Can ISPC sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Commercial Physical & Biological Resarch peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $1.9M and free cash flow of -$4.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is ISPC's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
ISPC Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for iSpecimen Inc. (ISPC) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Stock Titan • 1d ago
A 1-for-10 to 1-for-100 reverse split goes to iSpecimen (ISPC) voters October 30. Stock Titan report covering iSpecimen Inc. (ISPC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
12 Health Care Stocks Moving In Thursday's After-Market Session Benzinga report covering iSpecimen Inc. (ISPC) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Stock Titan • 1d ago
Healthy donor blood is generally shipped the day it's collected, aiming for next-day delivery. Stock Titan report covering iSpecimen Inc. (ISPC) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH https://www.siam.in/ • 1d ago
iSpecimen (ISPC) Falls -0.76% — Watching $0.86 Support 2026-10-20 - Algorithmic Stock Picks https://www.siam.in/ report covering iSpecimen Inc. (ISPC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 4d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million. Intensity Therapeutics
🟡 MARKET WIRE ChartMill • 4d ago
After-Hours Market Movers: Oct. 29, 2026 Gainers and Losers Postmarket movers for Oct. 29, 2026: top after-hours gainers included SLGB, BURU and WKHS, while GCTK, LNAI and ATEC led the decliners.
🟡 MARKET WIRE Yahoo • 4d ago
iSpecimen Offers Next-Day Healthy Donor Blood and Launches Development of AI Agent Woburn, Massachusetts--(Newsfile Corp. - October 29, 2026) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), a provider of human biospecimens, today announced expanded access to fully consented, prospective
🟡 MARKET WIRE Benzinga • 12d ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Biohaven (NYSE:BHVN) shares increased by 39.3% to $16.37 during Thursday's pre-market session. The company's market cap stands at $1.7 billion. Vogenx (NASDAQ:VOGX) stock rose 22.05% to $24.89. The
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
ISPC Bull vs. Bear Conversation Board — What's Your Call at $0.83?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ISPC 🐻 33% BEARISH CONVICTION
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH
🎯 Target: $1.10 (+32.5%)
📌 Pinned Debate Cash of $6.9M in FY 2025 exceeds that year's -$4.2M free cash flow outflow, per the SEC financials.
Long ISPC at $0.83 targeting $1.10. Cash of $6.9M in FY 2025 exceeds that year's -$4.2M free cash flow outflow, per the SEC financials.. Institutional whale score is 3/20 and the risk/reward vs. the $0.75 52-week low is skewed heavily in favor of bulls.
ArenaChamp_24 🐂 BULL
@ForensicBear Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Commercial Physical & Biological Resarch. If gross margin (11.2%) holds, EPS grows into the multiple faster than bears think.
FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH
🎯 Target: $0.71 (-14.5%)
Spot @ $0.83 Net income was negative in every reported period while revenue fell from $9.9M to $1.9M, per the SEC financials.
Fading this rally in ISPC at $0.83. Net income was negative in every reported period while revenue fell from $9.9M to $1.9M, per the SEC financials.. With a beta of 1.0 and the stock sitting at $0.83 (52-wk range $0.75–$32.96), the easy multiple expansion is already priced in.